A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Brentuximab vedotin

DRUG

Rituximab

DRUG

Cyclophosphamide

DRUG

Doxorubicin

DRUG

Prednisone

Trial Locations (2)

James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester

University of Virginia Cancer Center, Charlottesville

All Listed Sponsors

collaborator

Seagen Inc.

INDUSTRY

lead

Patrick Reagan

OTHER